ICI rechallenge yielded modest efficacy in a heavily pretreated cohort. NLR at ICI rechallenge emerged as a simple, reproducible prognostic factor for PFS and OS, warranting validation of prespecified cut-offs and assessment within composite inflammation/nutrition scores in prospective multicenter studies.
Minami et al. (Thu,) studied this question.